Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • lexogen
    Registered Vendor
    • Aug 2012
    • 49

    #1

    Announcement of the Test Program for Spike-In RNA Variants (SIRVs)

    Lexogen has developed Spike-In RNA Variants (SIRVs) for the quantification of mRNA isoforms in Next Generation Sequencing (NGS). The SIRVs address the issue of the lack of the transcript spike-in controls of representative complexity for evaluation of RNA-Seq steps. These are 69 artificial transcript variants derived from 7 human model genes, which were extended by exemplary isoforms to comprehensively reflect known variations of alternative splicing, alternative transcription start- and end-sites, overlapping genes and antisense transcription. Moreover, the SIRVs sequences were modified to conform to the GT-AG exon-intron junction rule with few exceptions harboring the less frequently occurring natural variations GC-AT and AT-AC.

    The SIRVs are already available for testing. Thus, if you want to evaluate your existing RNA-Seq pipeline and/or explore new experimental approaches, be it in library preparation, sequencing and/or data analysis, you can already include the SIRVs into upcoming experiments of your interest. The aim of this Test Program is to obtain a broad test base with respect to input material, library preparation, sequencing platform / sequencing modes, as well as the subsequent data processing routine. All participants should profit from this broad test scope, which excels the capacity of individual facilities.

    For more details and application for the Test Program please visit the webpage http://sirvs.org/.

    If you have any questions please do not hesitate contacting us at [email protected].

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    Yesterday, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Yesterday, 05:39 AM
0 responses
11 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-13-2026, 09:56 AM
0 responses
14 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-09-2026, 11:14 AM
0 responses
27 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 09-29-2026, 09:51 AM
0 responses
77 views
0 reactions
Last Post SEQadmin2  
Working...